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In this study, the relationship between average absolute telomere length and metformin use was 
examined. Human blood samples were obtained from 106 participants ranging from 42-100 
years old. Samples were split into four cohorts for analysis: non-type 2 diabetics not taking 
metformin (Cohort 1), type 2 diabetics taking metformin (Cohort 2), type 2 diabetics not taking 
metformin (Cohort 3), and non-type 2 diabetics taking metformin. DNA from blood samples 
were extracted and purified using an  and average absolute telomere length was measured using 
quantitative polymerase chain reaction (qPCR). The average absolute telomere length increased 
with age for Cohort 2 samples and decreased slightly with age for Cohort 1 samples. This led to 
the mean average absolute telomere length of Cohort 2 beginning as a lower value than Cohort 1 
and then matching and later surpassing the Cohort 1 levels with increased age. This trend was 
intriguing but showed no statistical significance between the mean average absolute telomere 
length for Cohort 1 and Cohort 2. Cohort 3, however, had a mean average absolute telomere 
length which was considerably lower than Cohort 1 and 2. The difference between Cohort 3 and 
1 and Cohort 3 and 2 was statistically significant between the ages of 71-80. This lower average 
absolute telomere length in Cohort 3 when compared to Cohort 2 indicates that metformin use 
may reduce telomere shortening in older adults. Overall, the findings provide further evidence of 
metformin’s geroprotective effects, and indicate the need for further, more in depth studies in the 
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1: Literature Review/Introduction 
 
 For as long as humans have been aware of their own mortality, they have yearned for a 
greater understanding of the aging process and possible remedies for this invisible illness. 
Despite the fascination of many, the ’how’s’ and ’why’s’ of aging had remained a mystery for 
millennia. From Ponce de León’s epic voyage to the new world in search of the fabled ’Fountain 
of Youth’, to Countess Elisabeth Báthory’s macabre ritual of bathing in virgin blood with the 
aim of retaining her beauty and virility, mankind’s journey to cultivate a greater understanding of 
the aging process has been a long and storied one. With the dawn of the 20th century and the 
veritable Cambrian explosion of paradigm-shifting scientific discoveries that soon followed, 
humankind’s knowledge began to expand - if only modestly. It became well documented that the 
aging process had several intersecting etiologies, all with differing degree of impact from 
individual to individual. Later, genetics became well established as playing an important role in 
how one aged. However, knowledge about the impact of epigenetics and environmental factors 
were also found to be invaluable. 
 Pharmacological studies looking for methods of mitigating the effects of aging were also 
undertaken. Eventually, the antihyperglycemic drug, metformin, used primarily to treat 
symptoms of type 2 diabetes, was examined and was found to show promising anti-aging 
properties. Although this geroprotector may have initiated many studies to investigate its 
effectiveness at treating various diseases, little has been done to examine its role in preventing 
DNA degradation, particularly telomere reduction, that could lead to aging.  
This study aims to examine the role metformin has on human telomeres, the protective 
caps which protect DNA from degradation over time. It is conducted with the aim to continue in 
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furthering our knowledge of the aging process and potentially lead to notable revelations in the 
future.  
 
1.1 Use of metformin in type 2 diabetes therapy 
 
 Currently, metformin is the most widely prescribed drug to treat hyperglycemia for 
individuals with type 2 diabetes (1). It is estimated to be prescribed to over 120 million people 
worldwide (1). Type 2 diabetes, also referred to as non-insulin dependent diabetes or adult-onset 
diabetes, encompasses those who have insulin resistance and relative (as opposed to absolute) 
insulin deficiency (48). It is the most common form of diabetes, making up 90-95% of all cases 
(48). People with type 2 diabetes have elevated levels of blood glucose, and since they do not 
have insulin levels to match this increased amount of glucose, their insulin secretion is said to be 
defective and insufficient to compensate for insulin resistance (48). Metformin treats type 2 
diabetes by increasing sensitivity to insulin, specifically in the liver (46). It also functions as a 
caloric restrictor, reducing the amount of glucose taken in the body. 
 
1.2 Metformin development and history 
 
Metformin, also known as dimethylbiguanide (Figure 1), is an oral antihyperglycemia 
drug that has over recent decades become the primary treatment for type 2 diabetes. Origins of 
the drug begin with the precursor plant Galega officinalis L. which was a traditional herbal 
remedy used to treat worms, epilepsy (‘falling-sickness’), fever, and pestilence (49). The herb 
was eventually found to contain high concentrations of guanidine, a chemical that was soon 
realized to be effective in lowering blood glucose levels (49).  
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 In 1922, Werner and Bell chemically synthesized dimethylbiguanide (Figure 1), later 
called metformin (50). It was seven years later, in 1929, when its glucose-lowering properties 
were discovered (49). In the 1940s, metformin was discovered to be an effective treatment 
against malaria and influenza (49).  In 1957, Jean Sterne, a physician at Aron Laboratories in 
France investigated the effect metformin had on both type 1 and type 2 diabetics (49). He found 
that in some type 2 diabetics, metformin use would negate the need for insulin treatments, while 
lowering the necessary dosage requirements for other type 2 diabetic patients (49). However, 
these promising results were exclusive to type 2 diabetics, with type 1 diabetic patients still 
requiring insulin treatments (49). Metformin ultimately had relatively low prescription rates due 
to being weaker than other glucose-lowering biguanides (49). 
 However, by the 1970s many in the biguanide family, such as phenformin (Figure 1), 
were found to be linked to lactic acidosis and were discontinued from clinical use (49). Studies 
looking at the risk of lactic acidosis from metformin use found the incidence to be considerably 
lower than other biguanides and attributed most cases of lactic acidosis to contraindicated use 
(51, 52). Also, in some studies it was debatable whether incidences of lactic acidosis with 
metformin were greater than background rates for type 2 individuals (49). Although taking 
metformin was not found to be a significant risk for the development of lactic acidosis, the 
association with the notorious biguanide family resulted in plummeting prescription rates, 




Figure 1: The structure of biguanide and other related compounds including Metformin (49). 
 
 
 A resurgence of research in the 1980s and early 1990s resulted in the development of 
fixed-dose combinations of metformin with sulfonylureas, as well other classes of oral glucose-
lowering agents (49). The unique benefits and usefulness of metformin, discovered through this 
research, led to the drug being approved for therapeutic use in Canada in 1972 (53). In 1995 it 
received FDA approval for use in the United States (49). A long-term retrospective study in the 
UK in 1998 cemented metformin as the preferred initial therapy to manage type 2 diabetes-
related hyperglycaemia (49). The study noted that, alongside its glucose-lowering effects, 
metformin had the benefit of weight neutrality, low hypoglycemia risk, and reduced 
cardiovascular risk (49, 54). Because of these benefits, its extensive history of clinical use, and a 
possible reduction of cancer incidence, metformin is currently globally recognized as the first-
line of oral therapy treatment for type 2 diabetes (55, 56, 57, 58).  
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1.3 Metformin molecular action and effects 
 
Due to its similarity to other biguanides, yet uniqueness in being a considerably safer 
treatment, there has been a great deal of interest in deciphering the drug’s mechanism of action. 
Currently, researchers are still in the process of uncovering all the therapeutic biochemical 
mechanisms initiated by the drug. These processes are difficult to definitively attribute to 
metformin, as it passes through many regions of the mammalian anatomy and interacts with 
multiple biochemical pathways during the organism’s anatomical lifespan. Supra-pharmaceutical 
levels of metformin are required to achieve the desired therapeutic effects for type 2 diabetics, 
strongly supporting the notion that the therapeutic effects are not solely attributed to the 
modification of a single/specific protein target (55). 
The pathway of orally administered metformin passes through a number of organs within 
the body before its elimination (Figure 2). Orally administered metformin is absorbed by 
enterocytes in the apical membrane of the intestine via the plasma monoamine transporter 
(PMAT) and organic cation transporter 3 (OCT3) (59). It exits these cells via the organic cation 
transporter 1 (OCT1) molecule of the basolateral membrane (59). Next, metformin is delivered 
to the liver via the portal vein where it is taken up by the hepatocytes (59). It enters the 
hepatocytes via the OCT1/3 molecules and is excreted into the bloodstream and bile through the 
multidrug and toxin extrusion 1 (MATE 1) transporter molecule (59). Lastly, metformin reaches 
the kidneys, entering the renal epithelial cells through the organic cation transporter OCT2 
transporter molecule (59). It is eliminated from the renal epithelial cells unchanged via the 









It is widely accepted that metformin is able to lower glucose levels in the body through 
the stimulation of adenosine monophosphate-activated protein kinase (AMPK), an essential 
cellular energy sensor and regulator (59). The AMPK is a multi-subunit enzyme that regulates 
lipid biosynthetic pathways through the phosphorylation and inactivation of various key enzymes 
such as acetyl-CoA carboxylase (ACC) enzyme (60). The AMPK’s regulatory effects are able to 
stimulate Adenosine Triphosphate (ATP)-producing catabolic pathways (glycolysis, fatty acid 
oxidation, and mitochondrial biogenesis) and to inhibit ATP-consuming anabolic processes 
(gluconeogenesis, glycogen, fatty acid, and protein synthesis). Metformin’s stimulation of 
AMPK can cause a reduction in glucose levels by promoting hepatic gluconeogenesis, increasing 
liver insulin sensitivity, increasing muscle glucose transport, decreasing the amount of plasma 
glucose and triglycerides, and increasing fatty acid oxidation in the adipose tissue (2, 21). The 




In the liver, AMPK is able to partially inhibit gluconeogenesis by phosphorylating the 
CREB-binding protein (CBP) (21). Protein kinase C initiates the dissociation of the 
gluconeogenic CREB-CBP (CREB binding protein)-TORC2 (transducer of regrulated CREB 2) 
transcriptional complex, resulting in a chain reaction that causes the transcriptional machinery to 
be disassembled and the enzyme genes essential for gluconeogenesis, phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) to have their expression inhibited 
(21).  
 The activation of AMPK by metformin has also been shown to affect lipid and 
cholesterol synthesis in the liver, muscle and adipose tissues by decreasing both fatty acid 
synthase (FAS) expression and activating malonyl-CoA carboxylase (21). These desired results 
can be obtained indirectly by the inactivation of ACC and 3-hydroxy-3-methylglutaryl (HMG)-
Co reductase (21). Furthermore, the action of AMPK is able to inhibit adipogenesis through the 
inhibition of the activity of sterol regulatory element-binding protein-1c (SREBP-1c), a 
transcription factor that is essential for fatty acid synthesis (21). Stimulation of AMPK is also 
able to increase glucose uptake in the skeletal muscles by inducing the enzyme hexokinase II 
expression and upregulating the transcription of the GLUT4 (glucose transporter type 4) gene 
(21). 
There are also other AMPK-independent pathways that have been suggested as 
mechanisms of action of metformin, such as activating changes in the gut or intestinal 
microbiota. The intestines also play an important role in metformin’s glucose-lowering effect by 
facilitating uptake and utilization of glucose (3, 4). Metformin can also act on MAPK- and PKA-
dependent mechanisms as an alternative to mechanisms that utilize AMPK (22). Metformin’s 
ability to decrease cyclic adenosine monophosphate (cAMP) production inhibits catecholamine-
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stimulated lipolysis, reducing both MAPK- (Mitogen-Activated Protein Kinases -) and PKA- 
(Protein Kinase K-) dependent activities (21). In addition, adiponectin is also activated by 
metformin and can further stimulate AMPK to reduce hepatic lipid accumulation by both 
increasing β-oxidation and decreasing de novo synthesis of fatty acids (21). 
Together, these combined molecular effects are able to result in an overall slowing of the 
aging process and an extension of longevity. Every year, more and more knowledge is generated 
about metformin’s various biochemical mechanisms (Figure 3). Although a better understanding 
of how metformin affects the human body is beginning to take form, more research is still 
required to better understand the minutia of these internal biochemical processes.  
 
 
Figure 3: A visual summary of metformin’s antihyperglycemic effects (21). 
 
 




Because comorbidity is frequently found with cancer and type 2 diabetes, there has been 
a great deal of research looking into metformin’s effect on various forms of cancer. Insulin and 
insulin-like growth factor 1 (IGF-1) play an important role in regulating cell survival and 
mitogenesis (61). Both these growth factors are present in cancers of the breast, liver, colon, 
pancreas, and skin, hinting at the possibility of metformin to reduce the cancerous growth 
patterns associated with these stimuli (62). This possibility is further supported by evidence 
showing that caloric restriction (CR) can reduce IGF-1 activity, simultaneously reducing the 
incidence of cancer in in vivo animal models (63). 
 Several studies have examined metformin’s effect on cancer, and the majority of 
evidence indicates that metformin treatments have the potential to reduce mortality rates and 
improve longevity for patients affected by breast, liver and ovarian/endometrial cancers (61, 66, 
67). Other studies have shown that metformin treatments may be beneficial for individuals with 
colorectal, pancreatic or prostate cancer (61, 64, 65). A comprehensive meta-analysis by 
Franciosi et al. (68) examined the relationship between metformin use and overall mortality and 
found that there was an overall 35% reduction in cancer mortality rates observed in  patients 
taking metformin. Furthermore, metformin has also shown to improve the effectiveness of 
chemotherapy while reducing some of the side effects (61, 69, 70). 
 Metformin has also been shown to be a useful preemptive treatment for individuals 
diagnosed with prediabetes (71). Alongside lifestyle changes, early metformin treatment was 
found to be effective in the prevention of type 2 diabetes (71). It should be noted that lifestyle 
changes were found to have a greater impact as a preventative measure than the metformin 
treatments (71). Similarly, metformin was also shown to be moderately beneficial for treating 
obesity, yet lifestyle changes were still found to be more effective overall (72). 
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 There have been many studies looking at the benefits of metformin therapy to treat 
polycystic ovary syndrome (PCOS) as insulin resistance and hyperinsulinemia have been shown 
to contribute to the condition (73). Hyperinsulinemia initiates hyperandrogenism, which leads to 
anovulation and infertility (73). It has been found that metformin is quite effective in reversing 
the metabolic abnormalities associated with PCOS leading to the establishment of regular 
menstrual cycles and improved fertility (73, 74).  
Metformin use has also been shown to be beneficial in improving cardiovascular health.  
Use of metformin has been shown to normalize blood pressure, improve the metabolic risk factor 
profile, and increase the fibrinolytic activity in individuals with hypertension (75). Overall, 
metformin therapy has been found to reduce the risk of cardiovascular-related morbidity and 
mortality (76).  
 
1.5 Metformin’s effect on lifespan in animal models 
 
Metformin’s wide range of health benefits and diverse biochemical pathway interactions 
has led to a great deal of interest in its effects on lifespan and the aging process(es). Currently, 
much of the aging research available on metformin has existed through studies of animal models.  
Metformin treatment increased lifespan in several mice studies. It improved health and 
lifespan in male mice, where long-term treatment with metformin (0.1% w/w in diet) starting at 
middle age was effective in increasing mean lifespan by around 6% (9). However, a higher dose 
(1% w/w diet) was toxic to the mice, shortening mean lifespan by 14% (9). This is likely due to 
lactic acidosis, as high doses of metformin have been associated with its development (10). Low 
doses of metformin gave the mice increased sensitivity to insulin, reduced low-density 
lipoprotein (LDL) and cholesterol levels without a decrease in caloric intake, and improved 
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physical performance. The lack of decrease in caloric intake is important because it shows that 
any results found were not a result of CR. These results mimic the benefits of CR, which suggest 
that metformin acts in a similar way with respect to its benefits in extending lifespan and health, 
and suggest that metformin prevents the onset of metabolic syndrome. At the molecular level, 
metformin increased antioxidant protection and AMPK activity, reducing chronic inflammation 
and overall oxidative damage accumulation (9). In the study by Martin-Montalvo et al. (9) the 
serum level of metformin was found to be one order of magnitude higher than what is found in 
diabetics on metformin, so the effects of this drug may be less pronounced in people taking 
metformin as they may not receive a high enough dose to realize the increased health and 
lifespan benefits (9). 
Metformin may need to be taken from a young age to fully realize its anti-aging effects. 
In a study done on female SHR mice, the mean lifespan of the mice was increased significantly 
when treatment with metformin was initiated at a young age, insignificantly at middle age, and 
not at all at an older age (11). The treatment that started at the age of three months increased 
mean lifespan by 14% and maximum lifespan by 1 month (11). The treatment started at 9 months 
only increased mean lifespan insignificantly by 6%, while the treatment started at 15 months 
failed to increase mean lifespan at all (11). If this mouse model holds true in humans, this 
suggests that treatment with metformin over a longer period of time can affect lifespan but would 
not be as effective if started later in life, which is often when most people begin to think about 
the consequences of aging (11). Another study performed on female SHR mice corroborated 
these results. Compared to control mice, mice receiving daily 100 mg/kg treatments of 
metformin had mean lifespan increase by 38%; the mean life span for the last 10% of survivors 
increased by 21%, and maximum life span increased by 2.8 months (+10%)(12). 
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Similarly, in two other studies done on female HER-2/neu mice, metformin increased 
mean lifespan by 4-8%, and increased the maximum lifespan by 1 month (13, 14). The increase 
in lifespan was attributed to the inhibition of mammary tumor development (13, 14). Metformin 
treatment was initiated at 2 months of age, which compared to the studies mentioned above is a 
relatively young age (13, 14).  
In a study done on 129/Sv mice given 100 mg/kg daily for 24 months, females had a 5% 
increase in mean lifespan while males had a 13% decrease (15). This was the first study that 
showed a difference in metformin’s effect on males versus females, which is an important factor 
as most of the mouse studies mentioned here were done on female mice. The authors suggested 
two possible reasons for this difference: fundamental differences in the mechanisms of aging in 
females and males and/or that the target of metformin is different in females versus males (15). 
Regardless of sex-related differences in mammalian response to metformin treatment 
metformin’s effects appear to apply to other animal clades as well. Metformin has been shown to 
increase health and extend median lifespan in C. elegans L. in a similar mechanism as CR, 
independent of the insulin-signaling pathway (16). Metformin slowed locomotory decline in 
nematodes, suggesting that metformin can promote or extend youthful physiology (16). The 
authors demonstrated that metformin acts as a CR mimetic by showing that in a nematode strain 
that induces CR, metformin does not further increase the benefits of a CR diet, but instead shows 
a negative impact on lifespan (16). This is likely due to both CR and metformin treatment 
together being too extreme to be beneficial. Also, metformin treatment showed delayed egg-
laying, decreased age pigment levels, reduced progeny production and decreased fat, all of which 
are indicators of CR (16). This study also investigated the biochemical roles of the energy sensor 
AMPK and the AMPK-activating kinase LKB1 (liver kinase B1), which were both activated by 
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metformin (16). Both AMPK and LKB1 were found to be essential for improving health benefits 
of C. elegans, suggesting a conserved metabolic loop across various phyla (16). The study also 
found that the transcription factor SKN-1 plays an essential role in the extension of health in C. 
elegans (16). SKN-1 functions in nematode sensory neurons to promote dietary restriction 
longevity benefits and in intestines, helping to improve resistance to oxidative stress (16). In 
order for metformin-mediated health expansion to occur, SKN-1 must be expressed in both the 
neurons and the intestines, lending support to the notion that that metformin functions as a 
middle-age geroprotector through the regulation of CR metabolism and anti-oxidant defenses 
(16). These revelations about SKN-1 can become pharmacologically important when applied to 
the orthologous nuclear respiratory factor (Nrf) mammalian transcription factors Nrf1 and Nrf2, 
which are able to activate genes encoding phase 2 detoxification enzymes (16). The Nrf2 confers 
several defensive health-promoting effects in mammals and may be able, through the use of 
metformin, to combat neurodegeneration, chronic inflammation, and cancer in mammals (16). 
Another study done by Cabreiro et al. (17) showed that metformin may slow aging in 
nematodes by regulating their gut microbial folate and methionine metabolism. This finding 
raises the possibility that metformin might therefore also influence mammals by affecting their 
microbial metabolism or composition by promoting a better balance of gut microbiota species 
(17). They found that metformin at doses of 25, 50, and 100 mM increased the mean lifespan of 
C. elegans by 18%, 36%, and 3%, respectively (17). Both studies above noted that metformin 
increases lifespan via AMPK-dependent activation of SKN-1, but the Cabreiro et al. (17) study 
concluded that this is because they promote resistance to biguanide toxicity (16, 17). Both 
studies noted that as the concentration of metformin is increased, there is a point in which the 
effects become detrimental and actually shorten lifespan, which is likely due to drug toxicity. 
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Both studies discovered that when a CR diet was induced, metformin had the opposite effect and 
shortened lifespan (16, 17). 
Overall, the research data on metformin gathered from animal models provides some 
intriguing revelations. It seems that the most animal models indicate the importance of biological 
sex as well as age of treatment initiation in determining metformin’s effect on aging and 
longevity. Interestingly, evidence may also indicate that a CR diet taken alongside metformin 
may negate some of the drug’s anti-aging properties. This is a point of interest as it has been 
demonstrated that lifestyle changes such as CR diets undertaken simultaneously with metformin 
treatments are the most effective for preventative treatment of type 2 diabetes (71). It has also 
been shown that metformin use, combined with a CR diet, led to additive health benefits as 
opposed to worsened outcomes (20). Perhaps this difference could be indicative of specific 
differences in the way metformin affects biochemical pathways. Other evidence that points to 
metformin’s diversity in biochemical influence comes from the fact that higher doses in mice 
models resulted in lifespan shortening, while in humans supra-pharmaceutical doses are required 
to be effective (9). The vastly different outcomes between mouse and human responses to large 
doses could be due to high doses of metformin in mice may cause lactic acidosis, while the risk 
for lactic acidosis in humans with high does is low (10, 49, 51, 52, 55). These findings indicate 
the delicate balance required to provide optimal therapeutic treatment with metformin.  
 
1.6 Metformin mimics caloric restriction 
 
Metformin has been described as a geroprotector, which is a drug that decreases the rate 
of aging and therefore extends lifespan. The main explanation for metformin’s lifespan 
increasing benefits is that it is a CR mimetic (5). Caloric restriction is simply restriction of food 
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intake, which results in a restriction in the intake of energy. Caloric Restriction extends lifespan 
by delaying or slowing the aging process (5). Specifically, evidence suggests that maximum 
lifespan can be increased through CR and, therefore, through metformin usage as can be seen in 
the Drosophilia melanogaster L. model (24). 
Excessive caloric intake can lead to obesity that in turn can increase the instance of age-
related ailments such as diabetes, atherosclerosis, thrombosis, hypertension, various forms of 
cancer, coronary heart disease, stroke, osteoporosis, and Alzheimer’s disease (23). Since caloric 
intake is so closely related to age-related diseases, it can be logically concluded that drugs that 
mimic CR could in turn regulate the aging process (23). 
Caloric Restriction has shown health benefits in flies, rodents, monkeys, and humans. In 
many animal models, it has been shown to extend mean and/or maximum lifespan, as well as 
delay age-related physiological changes or age-related diseases such as type 2 diabetes. It has 
been shown to have effects on the insulin and IGF-1 signaling systems, as well as altering the 
activity of transcription factors such as AMPK and TOR (target of rapamycin) (6). The 
insulin/IGF-like signaling (IIS) and nutrient response pathways, which are defined by the 
mechanistic target of rapamycin (mTOR), control aging and age-associated pathology in worms, 
insects, yeast, and mammals (7, 8).  
Further benefits have also been shown by implementing additional CR alongside use of 
metformin (20). In a study examining male OLETF rats with initial ages of 20 weeks, subjects 
were given daily doses of 300 mg/kg for 12 weeks (20). Both metformin treatment and CR diets 
were found to cause decreased adiposity in the rats (20). The combination of CR and metformin 
treatment provided more effective post-challenge glucose tolerance (20). The combination 
treatment also reduced levels of serum alanine aminotransferases, resulting in lowered liver 
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triglyceride levels which could lead to improved conditions for nonalcoholic fatty liver disease 
(NAFLD) (12). The combination treatment of CR and metformin reduced the levels of the 
hepatic lipogenesic ACC and stearoyl-CoA desaturase-1 (SCD-1) (20) and increased the amount 
of hepatic mitochondrial activity (shown through the increased levels of β-hydroxyacyl CoA 
dehydrogenase (β-HAD)) (20). Overall, this indicates that therapeutic metformin treatment and 
CR independently improve glycemic control and NAFLD outcomes and likely act via different 
biochemical pathways (20). 
 
 
1.7 Metformin may reduce oxidative damage 
 
Through the body’s use of oxygen, potentially deleterious reactive oxygen metabolites, 
such as superoxide, ozone and hydrogen peroxide (H2O2) are generated (24). An overabundance 
of these oxygen molecules can lead to an aging process known as oxidative stress (24). Over 
time, the imbalance between prooxidants and antioxidants will result in enough oxidative stress 
to produce oxidative damage in molecules such as carbohydrates, nucleic acids, lipids, and 
proteins and thus alter their structure and impair their functions (24, 75). The degree of oxidative 
damage increases with age and is believed to be the major cause of cellular senescence and is 
considered to be one of the modalities of aging (24). 
Many studies have shown that oxidative damage can be mediated via CR, further 
suggesting that CR can counteract the aging process (24). Caloric Restriction reduced the 
metabolic rate of Fischer rats if CR treatments were started at 6 months of age (25). These results 
were also replicated in mice, with their resting temperature dropping by 13ο C (24). The body 
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temperature in rats was also shown to drop due to CR, but only by 2ο C (26). This indicates that 
CR decreased oxygen consumption and subsequently reduced oxidative damage (28). 
There is also evidence that metformin’s CR mimicking action can mediate the reduction 
of harmful oxidants in humans. The generalized action of CR has been found to be responsible 
for reducing oxidative damage in the body, increasing maximal life span and indicating overall 
anti-aging benefits (27). 
For example, one study by Rabbani et al. examined how metformin affects oxidative 
damage in apolipoprotein B100 of LDL particles in blood (28). High levels of LDL particles in 
blood are a strong indicator of type 2 diabetes-related cardiovascular disease as it indicates 
ineffectual LDL clearance from LDL receptors and hepatic over-secretion of apolipoprotein 
B100 (28). Along with oxidation of apolipoprotein B100, protein glycosylation and nitration also 
contribute to high LDL particles levels (28). Venous plasma LDL composition from type 2 
diabetics and healthy control patients was analyzed through stable isotopic dilution analysis 
tandem mass spectrometry (28). The results indicated that metformin decreased the amount of 
arginine-derived advanced glycation end products and oxidative damage in apolipoprotein B100 
of LDL (28). 
In addition to its role in reducing oxidative stress-related CR in type 2 diabetes, 
metformin also reduces oxidation of other biomolecules. For example, another study by Algire et 
al. (29) elucidated the beneficial effects metformin can have on DNA damage caused by 
oxidative stress. The study looked at reactive oxygen species (ROS) related to DNA damage and 
mutations. Several AMPK+/+ and AMPK-/- mouse embryonic fibroblast (MEF) cell cultures were 
created and exposed to varying conditions that typically increase the amount of ROS. Metformin 
reduced paraquat-induced, but not H2O2-induced, elevations of ROS in an AMPK-independent 
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manner (29). This indicated metformin’s effectiveness in reducing endogenous ROS production 
(29). In paraquat-exposed cells, metformin reduced DNA double strand breaks and somatic cell 
mutation rates while also improving mouse survival (29).  
Multiple studies have looked at metformin’s ability to treat neurological ailments and 
ameliorate oxidative damage located in the brain and collectively suggest an extension of neural 
longevity. There are multiple benefits to metformin-mediated amelioration of neural oxidative 
stress including preventing apoptotic cell death, memory impairment, cerebral ischemia and 
epileptic seizures (30, 32, 33, 34). A study by Zhao et al. (30) on male C57BL/6 mice found that 
metformin treatments were able to mitigate neural oxidative stress and cognitive impairment 
associated with seizures and epilepsy. Another study by El-Mir et al. (31) examined diabetes-
related neuronal disorders and the effect metformin treatments might have on longevity found 
that oxidative stress can increase instances of etoposide-induced cell death on primary cortical 
neurons taken from rats.  
Through further exploration of this topic by researchers, more effective metformin-based 
treatments can possibly be developed to produce more optimal patient outcomes. Collectively, 
the majority of research findings indicate the effectiveness of metformin treatment in type 2 
diabetics to reduce the overall aging effects due to oxidative damage (29). 
 
 
1.8 Effects on telomere length 
 
Telomere length is another model of aging that is becoming more frequently used to 
measure longevity. Telomeres are specific sequences of non-coding DNA that ’cap’ the coding 
region of linear chromosomes, protecting it from degradation or enzymatic modification through 
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nucleolytic resection or fusion (35, 36). Structurally, telomeres are nucleoprotein complexes that 
include guanidine-rich repeated sequences within the DNA (36). The repeat sequence is the 
hexamer TTAGGG (35, 83). 
 
 
Figure 4: Location and structure of the telomere on a human chromosome (83). 
 
Telomeres have been shown to shorten with each cell division for many human tissues, 
disappearing completely after enough successive divisions (37). This is caused by a phenomenon 
known as the ’end-replication problem’, in which, due to the unidirectional 5’→3’ synthesis of 
DNA, some bases on the 3’ end remain uncopied after replication in the S phase (39). In the 
absence of telomeres, the DNA sequence can undergo degradation and the chromosome ends can 
become fused and destabilized. As a consequence, the cell will no longer be able to replicate, and 
enters a state of senescence in which the cell will cease to divide further (37).   
Limits to human cell division were first observed by Leonard Hayflick (35) who 
experimented with human tissue cells that were repeatedly cultured. Although Hayflick was able 
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to categorize the type of growth that occurred into three phases, with “Phase 3” displaying 
senescence, it was unknown at the time what caused this outcome (36). Senescence has since 
been shown to have many possible causes, many of which are environmental stresses (36). 
However, even in a stress-free environment, senescence is still inevitable (36). An accumulation 
of senescent cells in human tissue can result in the expression of the senescence-associated 
secretory phenotype (SASP) (119). Cellular senescence caused by a SASP has been shown to 
produce pro-inflammatory cytokines, chemokines, growth factors and proteases, leading to a 
damage in tissue structure and function that is characteristic of aging (119). 
The phenomenon of cellular senescence was first posited to be attributed to the gradual 
loss of telomeric DNA in the cells by Olovnikov in 1973 (122, 123). In 1992, Harley et al. built 
upon this concept, proposing that telomere length is shortened to a predetermined size in where a 
“genetic check-point” is reached, and the Hayflick limit is consequently initiated, halting cellular 
division (123). This phenomenon of progressive shortening with age was observed both in vivo 
and in vitro for somatic cells by Harley et al (123, 124). Gametes, such as sperm cells, do not 
display this, and their telomeres remain long without decreasing with age (123). This retention of 
telomere length is due to the presence of telomerase, which is active predominantly during 
gametogenesis (120, 123) 
Telomerase is a guanidine-rich ribonucleoprotein enzyme that can be used to synthesize 
the repeated TTAGGG/CCCTAA sequences of which telomeres comprise (38, 45). Telomerase 
acts similarly to a reverse transcriptase, and it is essential for complete replication of telomeres 
within DNA. It should be noted that, in humans, most somatic cells, such as fibroblasts, 
epithelial cells, melanocytes, endothelial cells, and astrocytes, do not express the telomerase 
enzyme and will thus eventually senesce (119, 45, 121). 
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Because of telomerase’s inactivation in somatic cell replication, as well as its noted 
activity in cancer cells, several studies developed ways to better understand the nature of this 
enzyme (18, 80, 120, 125, 126). Five independent research groups were able to concurrently 
clone human telomerase reverse transcriptase (hTERT), a subunit of telomerase (18, 80, 120, 
125, 126). Through the examination of hTERT reactivation, these studies were able to conclude 
that hTERT functions as the catalytic domain of telomerase and its expression is essential for the 
telomerase-mediate reverse transcription of human telomeres (18, 80, 120, 125, 126). 
In 1998, the researchers from the Geron Corperation were able to establish a causal 
relationship between the process of telomere shortening and in vitro cellular senescence (45). 
They demonstrated telomerase’s ability to extend the replicative ability of normal human somatic 
cells while maintaining their diploid status, growth characteristics, and expected gene expression 
pattern (45). Another study from the same year, by Vaziri and Benchimol, demonstrated similar 
findings, showing how the rejuvenation of telomerase activity in vivo was able to extend cellular 
life span through the increase in telomere length (19). 
Due to the natural shortening of telomeres in somatic cell with each cellular division, it 
can be logically assumed that there is a correlation between telomere length and aging. Many 
studies have confirmed this assumption, demonstrating strong correlations (40) (Figure 5). 





Figure 5: The rate of telomere shortening from early adulthood to old age using DNA samples 
extracted from whole blood (77). 
 
One preclinical study took a multimodal approach to examine metformin’s effects on 
longevity in prediabetic patients by examining several aging-related parameters (42). Gene 
transcription levels and protein levels of mTOR, p53, p66Shc, and sirtuin-1 (SIRT1) were 
examined in both individuals taking metformin and those assigned a placebo (42). SIRT1 activity 
as well as AMPK activation, telomere length, peripheral blood mononuclear cell (PBMC) levels 
and N-glycan levels were also studied in both individuals taking metformin and those assigned a 
placebo (42).  Out of 38 prediabetic patients, 19 were assigned to take 3x500 mg metformin 
tablets daily for two months, while the remaining 19 received the placebo treatment (42). The 
results found that some effectors of longevity pathways were modified (43). Metformin was 
found to moderately increase SIRT1 expression, reduce p70S6K phosphorylation, and favorably 
modified the plasma N-glycan profile (42). Telomere lengths of PBMCs were found to have 
increased significantly from the baseline levels after metformin treatments and did not increase 
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with placebo treatments (42). However the degree of change from the baseline  for both groups 
was not significantly different from each other (42). 
 The effect of metformin on reducing disease risk can be difficult to determine due to the 
complex etiology of many age-related human diseases. One study looked at potential links 
between type 2 diabetes, oxidative damage and colorectal carcinoma by measuring telomere 
length (43). While some of the study participants were taking metformin treatments, the efficacy 
of the drug was not tested (43). In addition to those participants undergoing treatments of 
metformin alone, others were prescribed treatments of sulfonylureas, both metformin and 
sulfonylureas in combination, and subcutaneous insulin (43). Overall, results indicated that mean 
colonic epithelial telomere length in participants with type 2 diabetes was not significantly 
different from the control values (43). Therefore, no link was found between telomere shortening 
due to type 2 diabetes and colorectal carcinoma. 
  Further colorectal cancer research examined how metformin affects telomeres in human 
colon carcinoma cells by studying the drug’s effects on the proliferation of SW-480 cells (44). 
Telomerase activity was examined through telomeric repeat amplification protocol (TRAP) 
silver staining (44). It was found that metformin treatments were able to decrease telomerase 
activity, inhibiting the growth of SW-480 cells (44).  
 Endometrial cancer cell proliferation was also examined in a study by Cantrell et al. (46) 
which investigated the effects metformin treatments had on human telomerase reverse 
transcriptase (hTERT) activity. The hTERT is an essential catalytic subunit of telomerase which 
is a guanidine-rich ribonucleoprotein enzyme that can be used to synthesize the 
TTAGGG/CCCTAA sequences in human telomeres (38, 45). Telomerase acts similarly to a 
reverse transcriptase, and it is essential for complete replication of telomeres, eliminating the 
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end-replication problem that would normally degrade the entire telomere sequence over time 
(45). qPCR was used on endometrial cell lines to measure hTERT gene expression (46). It was 
found that, within 24 hours of treatment with metformin, hTERT mRNA expression was 
decreased (46). As hTERT expression is considered a rate-limiting step in the production of 
telomerase and telomerase is needed for telomere extension, it appears that, in endometrial cells, 
metformin treatments will reduce telomere length. A reduction in telomere length could indicate 
a decrease in longevity for this particular cell type. Hanna and Zhou (47) further built upon this 
research to find that a combination treatment of metformin and paclitaxel may be more effective 
at maintaining telomere length. This potentiating effect seems to derive from metformin’s ability 
to inhibit cell proliferation while simultaneously modulating the mTOR pathway (47). 
1.8.1 Health conditions related to telomere length 
 
Damage to the chromosomal sequence can lead to many adverse health outcomes as well 
as increased mortality. Shortening of telomeres has been linked to atherosclerosis, dementia, 
post-stroke mortality, cognitive decline, diabetes, and cardiovascular disease (40, 86, 87, 88). 
Prevalence for these pathologies has been shown to increase as the telomere length decrease (40, 
86, 87, 88). 
The opposite is found in studies looking at telomere shortening and cancer. Many types 
of cancer have been found to increase in prevalence with longer telomere lengths. Telomerase 
has been shown to be active in tumorous tissues, leading to the prevention of telomere shortening 
(89). This immortalization of tissue results in oncogenesis and out of control cell growth (89).  
 




There are also several lifestyle factors that have been shown to correlate with telomere 
length. Oxidative stress has been shown to increase the rate of telomere shortening and the 
characteristic cellular senescence (90). Antioxidants will work contrary to this type of 
shortening, preventing telomere shortening (90). Life stressors, dietary differences, or childhood 
trauma have also been shown to correlate with telomere shortening (91, 92). 
 
1.8.3 Demographic factors related to telomere length 
 
Demographic factors such as gender and biogeographic ancestry also correlate with 
telomere length (14). Males, on average, have shorter telomeres than females and Caucasians, on 
average, have shorter telomeres than other biogeographical groups (40). 
 
1.9 Methods of measuring telomere length 
 
There is currently a diverse array of techniques that are being utilized to a high degree of 
effectiveness to measure telomere length. Southern blotting methods, widely considered to be the 
’gold standard’ technique for telomere length measurement, are but one way to accurately 
measure telomere length (93, 94). Quantitative PCR, quantitative fluorescence in-situ 
hybridization (q-FISH), Single Telomere length analysis (STELA) and other methods are also 
effective, each having their own unique set of advantages and limitations (93, 94). 
The Southern blot technique for measuring telomere length was originally developed by 
Kimura et al. (94) for examining leukocyte telomere length (LTL) in epidemiological studies. 
The procedure begins with genomic digestion with a ’cocktail’ of frequent cutting restriction 
enzymes (lacking telomeric and subtelomeric recognition sites) (94). The technique then makes 
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use of gel electrophoresis, followed by labeled probe hybridization for telomere sequencing (95). 
The different telomere lengths will be visualized through gel imaging, presenting as a smear to 
which the size and intensity can being assessed via comparison to a DNA ladder (93, 96). This 
method is also known as terminal restriction fragmentation, with the unit of measurement for the 
telomere length being telomere restriction fragments (TRFs) (94). 
Due to the frequency of use of the Southern Blot technique, the majority of literature 
contains the length of TRFs, allowing for more opportunities of direct comparison to occur (94). 
This method is also relatively cheap, with high reproducibility (93, 94). It also allows for the 
possible determination of telomere length distribution, however this is rarely completed in 
epidemiological studies due to difficulty in obtaining accurate gel measurements (93). One 
disadvantage is that the Southern blot method generally requires a substantial amount of DNA (3 
μg per sample) (93). It also requires the measurement of both the telomeric and sub-telomeric 
regions (93). Problems can also arise if the sub-telomeric regions lead to artificial inflation (93). 
There can also be variations in the TRF values if a different cocktail of restriction enzymes is 
used (97).  
Quantitative PCR is another method that is becoming more and more prevalent in the 
measurement of telomeres. Richard M. Cawthon (97) was the first to propose a method of 
measuring telomere length via qPCR. This method analyzes the relative telomere length per 
DNA sample (97). It compares the factor by which the sample differed from reference DNA and 
its ratio of telomere repeat copy number to single gene copy number (97). The ratio used is 
proportional to the average telomere length (97). Two serial dilutions are made with reference 
DNA (97). One serial dilution is completed with amplifications of the telomere repeat sequence 
for the reference DNA sample, and the other is completed with the amplification of a single copy 
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gene for the reference DNA sample (97). Once they have been amplified through the Real Time 
PCR thermocycler, the resultant Cq (equivalent to Ct, or cycle threshold) values for the serial 
dilutions can be plotted against the logarithmic values of their corresponding copy numbers in a 
standard curve. The tested sample can be compared to both serial dilutions to find the telomere 
repeat copy number and single gene copy number respectively (97). Relative telomere length is 
obtained by dividing the telomere copy number by the single gene copy number (T/S) (97). 
Cawthon’s qPCR method can produce results from more minute quantities of the initial sample 
than the Southern blot method (97). It also has the benefit of being able to provide a high-
throughput performance (93, 35).  
The Cawthon method was modified by Nathan J O’Callaghan and Michael Fenech to 
include an oligomer standard, allowing for the measurement of absolute telomere length instead 
of relative telomere length (35, 98). Absolute telomere length can be a direct comparison of 
results between other experimental values from other labs (35).  
In general, qPCR is able to produce results from more minute quantities of initial sample 
than the Southern Blot method because of this, buccal sampling, or any other low-quantity 
sampling, would be compatible with this methodology (93, 97). It also has the benefit of being 
able to provide a high-throughput performance, increasing the ease, amenability and speed of the 
analysis (93, 94, 35). One limitation of qPCR telomere analysis is that it has a high variance of 
between 5 and 10%, making it more difficult to notice differences between samples and control 
(93). Like the Southern blot techniques, qPCR-based techniques require high-quality, non-
compromised DNA samples (94). Also, the choice of the reference gene used can cause variance 
in the data due to differences in stability (93). Reference genes, such as 36B4, albumin and β-
globin, are common, yet there is no standard gene that is universally used (93).  
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The Southern blot and qPCR methods are also limited in that they can only determine the 
average telomere length of the specimen being evaluated, and do not provide information that 
specifically applies to the individual telomere lengths within a chromosome (94). The STELA 
method is a unique telomere measuring technique that does allow for the analysis of a single 
chromosome (37). This ligation-based method, originally developed by Baird et al. (37), targets 
the amplification of the telomeric portion of a single chromosomal end, by using primers that 
bind to the specific sub-telomeric sequences of a single chromosome. This procedure is only 
valid for measuring a small subset of chromosomes (Xp, Yp, 2p, 11q, 12q and 17p) (99). Also, 
differences in the rate at which specific telomeres shorten might render this technique ineffective 
in recognizing critically short telomeres (100).  
A modified method, referred to as the universal STELA technique, solves this problem 
by allowing any critically short telomere to be detected regardless of its location on the 
chromosome (100). This method involves three main steps digestion, ligation and amplification 
(100). The DNA of interest is first digested by a selection of restriction endonucleases, and then 
a ligation step allows for the suppression of the amplification of the intra-genomic fragment 
(100). Lastly, the samples are sequentially ligated and then amplified for the short telomeric 
regions (100). 
Both the original and modified STELA methods are able to detect telomeres in a single 
chromosome from very low-quantity samples (94). However, both methods are limited in that 
they are unable to measure telomeres having long lengths (over 8kb) (100). This could mean that 
these methods might be misleading in samples from cancer cells or from very young individuals 
(101, 89).  
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Fluorescence in situ hybridization (FISH) has frequently been incorporated in many 
methods that measure telomere length. Quantitative fluorescence in situ hybridization is one of 
these methods, measuring the length of the telomeric repeats (94). It was first developed Peter 
Lansdorp and colleagues and, shortly after, adapted by Krejci and Koch (102, 103). The q-FISH 
method differs from TRF and PCR-based assays by using cells as the substrate rather than the 
DNA itself (94). This method is accomplished by assessing the metaphase chromosomes or 
interphase nuclei following fluorescent labeling with a (CCCTAA)3 probe (94). Any remaining 
chromatin on the chromosome is visualized by a nonspecific DNA stain (such as 4',6-diamidino-
2-phenylindole [DAPI] or propidiumiodide (102). The probe typically chosen for the assay is a 
synthetic peptide nucleic acid (PNA) probe (94). This is because the probe has a neutral 
backbone, causing it to produce more efficient hybridization than DNA probes (104). The q-
FISH method is able to estimate the size of each of the 92 telomeres and it is not limited to 
measuring average or small-size telomeres (94). Another benefit is that this method can also 
recognize the ends of a chromosome that would typically be too small to adequately hybridize 
(94). The q-FISH method has been optimized for a variety of conditions and samples for 
biological testing (106). It has also been shown to be useful for measuring the telomere length in 
rare cells such as CD34+ cells in bone marrow from individuals suffering from dyskeratosis 
congenita (105). The main weakness of the metaphase q-FISH technique is its inability to 
measure telomeres in cells that are not actively undergoing mitosis (such as terminally senescent 
cells) (94). Its functionality is also limited in specimens with very slow proliferation rates (94). 
There are two main categories of q-FISH: metaphase q-FISH and interphase q-FISH (94). 
Metaphase q-FISH studies are useful for obtaining information about differences in telomere 
length between different chromosomes, and also for providing information about the frequency 
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of chromosomal instability associated with chromosomes with very short unhybridizable 
telomeres (107). This form of q-FISH is not suitable for large epidemiological studies due to it 
being labor intensive, expensive, and technically demanding (requiring experience with 
chromosomal banding patterns) (94). 
Interphase q-FISH was developed to overcome some of these limitations associated with 
metaphase q-FISH (94) utilizing interphase cells and its chromosomes rather than metaphase 
chromosomes. Interphase q-FISH is also able to assess telomere lengths in nuclei from a variety 
of different specimen types (94). Often in interphase q-FISH, a fluorescent signal obtained from 
a telomere-specific probe is compared to a centromeric probe or a differing coloured fluorophore 
(94). Next a ratio of signal intensity between the targeted sequences can be calculated (107). 
Interphase q-FISH is beneficial in telomere length analysis because it allows for the concurrent 
collection of information regarding telomere length and information about the tissue sample (94). 
It is also less labor intensive than metaphase q-FISH (94). This information can be used 
alongside immunostaining techniques to localize specific cells of interest in a process that is 
sometimes referred to as telomapping (108). A limitation of the interphase q-FISH technique is 
that it does not allow for the recognition of specific telomeres, or for the detection of 
chromosomal ends with very short unhybridizable telomeres (94). Also, the data is usually 
measurable in terms of a mean value for all 92 telomeres (94) and can be automated in a form 
known specifically as high throughput q-FISH (HT q-FISH) (101). This method was developed 
to maintain accuracy and improve efficiency in q-FISH, allowing for these methods to be used in 
larger epidemiological studies (93, 94, 101). The HT q-FISH method can also improve the 
efficiency of flow cytometry plus traditional FISH techniques (93). 
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Another method, flow cytometry plus FISH technique, was developed by Baerlocher et 
al. (109), in order to measure the mean telomere length with metaphase staining. Flow-FISH 
methodology also utilizes the (CCCTAA)3 PNA probe for quantification of the mean amount of 
fluorescence in the cells, and the average telomere length for that cellular population (110). This 
method could be used to measure from any subpopulation of circulating peripheral cells due to 
the initial flow cytometry step (109). Consequently, flow cytometry plus FISH was able to 
determine the telomere length for individual cells of a distinct cell type and the distribution of 
telomere lengths of that cell type (93). Furthermore, this method utilizes an internal reference 
control and highly specific nucleic acid probes to hybridize to the telomeric repeats, greatly 
improving the accuracy (93). Flow cytometry plus q-FISH is the first of the telomere assays to be 
used as a clinical diagnostic tool, assisting with the recognition of congenital dyskeratosis (111). 
This method can also allow for the inference of a three-dimensional distribution of telomeric 
signals in cells (112). Despite providing more information than other methods, flow cytometry 
plus FISH is quite expensive, highly inefficient, and requires a high degree of technical expertise 
that could limit its use in epidemiologic research (93).  
 The primed in situ (PRINS) method of measuring telomeres utilizes fluorescently tagged 
nucleotides and PCR techniques with telomeric primers which label the telomeric sequences in 
situ on metaphase chromosomes or interphase nuclei (113). This method is used in lieu of a PNA 
probe to label the telomeres in preparation for analysis using q-FISH methods (113). Therefore, 
the sample benefits and limitations of that method apply to PRINS techniques (93).  
The hybridization protection assay (HPA) involves the comparison of telomeric to Alu 
repeats present in a specimen (114). This method was designed to be faster and easier to read 
than the traditional Southern blot technique, improving the overall accuracy of the results (114). 
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This method involves adding the sample to a hybridization solution containing acridinium ester-
labeled probe, followed by a differential hydrolyzation with the unhybridized probe. The 
chemiluminescence results are then measured through imaging (114). Along with its speed 
(around 45 minutes), this technique does not require high quality DNA, or even large quantities 
(94). However, one limitation is that it is difficult to interpret the ratio values due to variation in 
the Alu repeat sequences between samples (93). Only a mean value of telomere length, with no 
cell- or chromosome-specific data is generated (93).  
Alternate methods also exist which quantify the length of the telomeric 3’overhang 
instead of the full telomeric length. Some techniques that follow this approach include 
telomereoligo (oligoneucleotide) length assistance (T-OLA), G-tail HPA, overhang protection 
assay (OPA), single-strand electron microscopy, primer-extension nick translation (PENT) and 
double-strand specific nuclease (94, 115, 116, 117, 118). These techniques have important 
biological applications and usually produce more focused outcomes (94).  
After considering the limitations and advantages of the telomere measurement methods 
above, as well as the equipment available in our lab, we chose to use qPCR in our study. Prior 
professional experience and success with this method as well as low processing time were 
deciding factors for choosing this method. Additionally, the relatively low cost of qPCR analysis 
allowed for this project to be economically feasible. 
1.10 Summary and future prospects 
 
 Currently, there are many studies examining the benefits of metformin treatment when 
prescribed for both its approved treatment of type 2 diabetes and off-label as a geroprotectant. 
Currently, more and more evidence supports the notion that metformin has geroprotective 
properties. With further information about the exact nature of metformin’s effects, and deeper 
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insight into its various interactions with biochemical pathways in the human body, therapeutic 
treatments can possibly be further developed.  
Prior to its approval as a geroprotectant, more research should be done on metformin’s 
effectiveness on preserving telomere length. Although studies have found that metformin can 
increase the length of telomeres and delay shortening, further human studies are needed because 
evidence indicates that metformin use may be more beneficial with more prolonged treatments. It 
would be valuable to have clinical trials that measure possible benefits of long-lasting metformin 
therapies. Future studies examining the specific benefits of the drug at all stages of life would 
also be useful. As well as subcategorizing subjects by age cohorts, it would also be useful to 
separate data based on biological sex due to the noted differences in health outcomes between 
men and women. Standardization of telomere length measurement methods is also needed to 
more easily compare treatment effects between studies, so that telomere measurements and 
general patterns and revelations from these prospective metformin studies can be replicated via 
differing telomere-measuring methods such as the Southern blot method, STELA or the q-FISH.  
With additional examination into this relatively novel area of research, further 
understanding of the effects metformin has on aging and longevity can be determined, with the 




2: Materials and methods 
2.1  Ethics approval and sample collection 
 
 All protocols were approved by the Lakehead University Research Ethics Board (Project 
#067 16-17). Primary patient recruitment was through the Curans Heart Centre, an outpatient 
cardiac clinic located in Thunder Bay, Ontario. Patients were recruited either through posters and 
pamphlets advertising the study or directly, where individuals taking metformin and/or who have 
type 2 diabetes, were informed about the study by their nurse practitioners and asked if they 
would be interested in participating in the study. All participants’ results of their telomere 
analysis (once the research has been published) along with a contextual comparison to the 
population average for their age cohort were emailed to each participant. 
 All participants were required to complete a consent form which included a brief 
questionnaire and a space to provide their email should they desire access to the results. The 
questionnaire asked the participant’s age, biological sex, whether they had type 2 diabetes, and if 
they were currently taking metformin. Once the consent form was completed, the nurse 
practitioner collected it and inputted the answers to the questionnaire and the patient’s personal 
information into a Microsoft Excel spreadsheet that was saved to a secure server. Each 
participant’s sample was assigned a random sample number and this number was recorded on the 
Excel spreadsheet along with their information. The Excel spreadsheet was only provided to the 
researcher once the data had been collected, analyzed, and tabulated for each random sample 
number, allowing the study to remain blind. Once all the information has been collected, the 
nurse practitioner took the blood with a 22 gauge needle and a 5 mL syringe. The blood was then 




2.2 Sample storage 
 
Blood samples were stored in a 2° C fridge temporarily (1-7 days). The samples were 
collected weekly from Curans Heart Centre and brought to the laboratory at Lakehead 
University. There, the samples were centrifuged at 13,000 rpm for 10 minutes. Afterward, the 
blood in the sample tube was separated into three components: the red blood cells at the bottom, 
the buffy layer containing the white blood cells in the center and the plasma at the top. An 
aliquot, 200 µL of the central buffy layer was removed via a micropipette and deposited into a 2 
mL microcentrifuge tube and labeled with the sample number. All lab work was conducted in a 
biosafety cabinet. All purified sample DNA solutions were stored in a -20° C freezer for up to 2 
months. 
 
2.3 DNA extraction and purification 
 
All DNA from the blood samples was extracted and purified using the 
Invitrogen PureLink Genomic DNA Mini Kit. All procedures followed the steps outlined in the 
PureLink Genomic DNA Kit user manual on pages 17, 23 and 24, which outline the protocol for 
a blood lysate DNA extraction and purification (76). In part 2 of the blood lysate extraction 
protocol (page 17), a suggested alternative to the default extraction procedure was implemented 
with 100 µL of the blood lysate sample used alongside 100 µL of phosphate buffered saline 
(PBS) (76). During the ’Eluting DNA’ step (page 24), 75 μL of the Genomic Elution Buffer was 
added to the washed DNA spin columns to produce purified DNA of a moderate concentration 
(as outlined on page 13). The newly purified DNA samples were stored in a -20° C freezer for up 




2.4 DNA quantification 
 
 Dyed master-mix solutions consisting of 198 µL of Tris-EDTA (TE) buffer, 0.5 μL 
QuantiFluor dsDNA dye and 2 µL of the purified sample were made and vortexed thoroughly. 
All samples were then quantified with a Promega Quantus fluorometer in triplicate. The 
concentration of the DNA solution was displayed through the Quantus software installed on an 
HP laptop computer. Data was then exported to Microsoft Excel, and the average concentration 
for each purified sample was determined. Quantifications of the telomere and 36B4 standards 
were also completed and would be necessary for the qPCR calculations in part 2.5. 
 
2.5 Preparation of samples, standards and primers for qPCR 
 
 Using the average concentration of each purified sample, the amount of double distilled 
water (ddH2O) required to dilute the sample to a concentration of 5 ng/µL was calculated (see 
Appendix A) (35). A 100 μM stock solution was created for both standards and both sets of 
primers (see Appendix B). Primers were further diluted with ddH2O by a factor of 10 into 1/10 
working primer solutions. Standards were also diluted with ddH2O into serial dilutions. Two sets 
of standards were created: a synthetic telomere standard to serve as a positive control reference 
for the amount of telomere hexomeric repeat sequences amplified per sample and a 36B4 
standard which encodes for the acidic ribosomal phosphoprotein P0 that serves as a positive 
control for the number of single gene copies (SCGs) amplified per sample (35). Both standards 
had 105, 106, and 107 serial dilutions included in each qPCR run. Based on the DNA 
concentrations quantified in part 2.4 by the Quantus fluorometer, the number of telomeres and 
SGCs were calculated for the telomere and the 36B4 standards respectively. These calculations 
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 All PCR runs were completed by first creating two qPCR master mixes (one for each 
primer set), which both consisted of 10 µL of PerfeCTa SYBR Green Supermix, 1 µL of the 
forward primer, 1 µL reverse primer, and 4 µL ddH2O (35). Each qPCR reaction had a master 
mix total volume of 16 µL added to 4 µL of the DNA sample (at a concentration of 5 ng/μL) 
(35). The qPCR master mix solution was added to each well of a 96 well PCR plate. Each 
sample, as well as the serial dilutions for both standards, were then added, in triplicate, to the 
master mix solution in each well. 
Once all the samples were added, the plate was then sealed and placed inside a Bio-Rad 
CFX96 Optics Module Real Time System C1000 Thermocycler. The thermocycler was set using 
the Bio-Rad CFX manager software. The cycling conditions were set to be 10 minutes at 95° C, 
followed by 40 cycles of 95° C for 15 seconds, 60° C for 1 minute, followed by a dissociation (or 
melt) curve. Once the qPCR was completed, the data were exported to a USB memory device 
and examined later with Microsoft Excel. 
 
2.7  Data analysis 
 
The results were analyzed using the Biorad CFX manager software and Microsoft Excel. 
The amplification curves were analyzed, and non-sigmoidal curves excluded from analysis. The 
Cq values were plotted against the known telomere quantities (in units of kb) and the SGC 
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numbers for both the telomere and 36B4 standard curve respectively. The Cq values from the 
samples amplified with the telomere primers were then compared to the telomere standard curve 
to elucidate the quantity of telomeres (in units of kb). All Cq readings were completed in 
triplicate and were averaged.  
Any outlier Cq values were eliminated before analysing the results. First the appearance 
of the amplification curves for each triplicated amplification runs was visually compared with 
one another. If one of the three curves appeared markedly shorter or steeper than the other two, 
with more than a 25% difference in height, the Cq value corresponding to that curve was 
eliminated. If any curve did not display the characteristic sigmoidal shape of a logarithmic 
amplification, it would be eliminated as well. All triplicated Cq values were also examined based 
on their numerical values. If a Cq value was markedly different than the other 2, with a percent 
difference of 25% or greater, it would be eliminated. If all Cq values were reasonably evenly 
dispersed, then all three values would have been calculated to determine the average 
The Cq values from the samples amplified with the 36B4 primers were also compared to 
the 36B4 standard curve to find the number of SGCs. The absolute telomere length per genome 
was determined by dividing the quantity of telomere by the SGC number. This number was 
further divided by 46 to determine the average absolute telomere length per chromosome. These 
calculations and a data sample are shown in Appendix C. 
Data was arranged into one of four possible cohort groups: Samples from non-type 2 
diabetic who did not take metformin (referred to as Cohort 1), samples from type 2 diabetics who 
did take metformin (referred to as Cohort 2), samples from type 2 diabetics who did not take 
metformin (referred to as Cohort 3), and samples from non-type 2 diabetics who did take 
metformin (referred to as Cohort 4). When analyzed, cohorts were not further subdivided into 
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ethnic origin, education, health/activity, or socio-economic status due to the limitations of the 
sample size. No information was taken about the dosage of the metformin or the treatment 
duration.  
The data was truncated to only include average absolute telomere lengths from samples 
of individuals 41 and older. This was because the data from participants under the age range of 
41-50 was homogenous, all belonging to Cohort 1. This information has limited use as it cannot 
be compared to other cohort groups within similar age ranges. Truncation of this data is useful as 
it allows the cohort groups to be more accurately compared and reduces the potential for the 
Cohort 1 data to be skewed due to having a large amount of younger samples. 
The final average absolute telomere length values were determined to be outliers if they 
were over 15 kb/chromosome or less than 0.1 kb/chromosome. Since it has been demonstrated 
through the literature that newborn telomere lengths typically fall between 15 and 20 
kb/chromosome, final average absolute telomere lengths over 15 kb/chromosome were 
considered to be outliers and were not included in the final analysis (78). Similarly, since 
average absolute telomere lengths under 0.1 kb/chromosome can be approximated to zero, any 
values below this threshold were also deigned to be outliers and were eliminated as well. 
2.8  Statistical analysis 
 
Regression analysis was first completed for all cohorts using IBM SPSS Statistics Data Editor. 
Next, t-tests were completed in Microsoft Excel 2016, which compared the data of Cohort 1 and 
Cohort 2, Cohort 1 and Cohort 3, and Cohort 2 and Cohort 3. Lastly, GraphPad Prism 7.05 was 








The four cohort groups are referenced as such: Cohort 1, Cohort 2, Cohort 3, and Cohort 
4. Cohort 1 contains participants equating to the non-type II diabetic and non-metformin 
samples, Cohort 2 equating to the type II diabetic and metformin samples, Cohort 3 equating to 
the type II diabetic and non-metformin samples, and Cohort 4 equating to the non-type II 
diabetic and metformin samples. 
 
3.1: Telomere length measurements 
 
Telomere length is provided in two forms for all samples: absolute telomere length per 
genome and average absolute telomere length per chromosome this allows for a more direct 
comparison to literature values. These measurements will be presented as mean values in units of 
mean average absolute. The telomere lengths were calculated (see example in Appendix A) and a 
compilation of all telomere length data obtained from separate qPCR amplifications (Table 1). 
Relevant, anonymized participant information is also presented here for direct comparison. The 
sex, age, diabetic status, and metformin use were all obtained from Curans Heart Centre and 
provided to the researchers after final calculations of telomere length. Samples from individuals 
over the age of 41 years were included in the analysis and interpretation. However all data is 







Table 1: A compilation of all quantified telomere lengths for the anonymized samples that were 
analyzed through qPCR amplification.  
 
Participant 















87 F 19 Non-Diabetic No 219.7747297 4.777711515 Cohort 1 
89 M 19 Non-Diabetic  No 174.7469764 3.798847312 Cohort 1 
91 F 19 Non-Diabetic  No 173.8538493 3.779431506 Cohort 1 
76 M 20 Non-Diabetic No 31.3279346 0.681042056 Cohort 1 
77 M 20 Non-Diabetic No 185.2797512 4.027820677 Cohort 1 
88 F 20 Non-Diabetic No 111.8700451 2.431957502 Cohort 1 
172 F 20 non-Diabetic No 13.41411709 0.291611241 Cohort 1 
10 F 21 Non-Diabetic No 870.5679517 18.92539025 Cohort 1 
15 M 22 Non-Diabetic No 182.5106574 3.967622986 Cohort 1 
155 F 23 non-Diabetic No 19.97200011 0.434173915 Cohort 1 
169 F 23 non-Diabetic No 162.3344055 3.529008815 Cohort 1 
84 M 24 Non-Diabetic No 182.4098576 3.965431686 Cohort 1 
175 M 24 non-Diabetic No 278.334279 6.050745195 Cohort 1 
1 F 25 Non-Diabetic No 128.6298684 2.796301487 Cohort 1 
92 F 25 Non-Diabetic  No 343.9382361 7.476918176 Cohort 1 
161 F 25 non-Diabetic No 328.4164295 7.139487599 Cohort 1 
7 F 26 Non-Diabetic No 208.2728414 4.527670466 Cohort 1 
160 M 26 non-Diabetic No 97.95116803 2.129373218 Cohort 1 
162 F 26 non-Diabetic No 286.0970147 6.21950032 Cohort 1 
40 F 27 Non-Diabetic No 443.2590608 9.636066539 Cohort 1 
115 F 27 Non-Diabetic  No 48.17006445 1.047175314 Cohort 1 
23 F 28 Non-Diabetic No 68.17244989 1.48200978 Cohort 1 
156 M 28 non-Diabetic No 75.62698996 1.644064999 Cohort 1 
157 F 28 non-Diabetic No 3.157556279 0.068642528 Cohort 1 
159 M 28 non-Diabetic No 154.4473124 3.357550271 Cohort 1 
170 M 28 non-Diabetic No 36.08898464 0.784543144 Cohort 1 
176 M 29 non-Diabetic No 1637.260978 35.59262996 Cohort 1 
14 F 30 Non-Diabetic No 248.1199084 5.393911051 Cohort 1 
2 F 35 Non-Diabetic No 3.191125551 0.069372295 Cohort 1 
13 M 35 Non-Diabetic No 160.8193517 3.496072864 Cohort 1 
8 F 36 Non-Diabetic No 4.660159858 0.101307823 Cohort 1 
9 M 39 Non-Diabetic No 0.377880114 0.008214785 Cohort 1 
42 F 39 Non-Diabetic No 67.3373124 1.463854617 Cohort 1 
22 F 42 Non-Diabetic No 153.324347 3.333137979 Cohort 1 
151 M 42 Type 2 Diabetes Yes 183.5970094 3.991239336 Cohort 2 
167 F 45 non-Diabetic No 26.84531477 0.583593799 Cohort 1 
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28 F 46 Non-Diabetic No 44.1599349 0.959998585 Cohort 1 
82 M 46 Non-Diabetic No 66.80082356 1.452191816 Cohort 1 
74 F 47 Non-Diabetic No 539.9246413 11.7374922 Cohort 1 
120 M 47 Type 2 Diabetes Yes 95.12266713 2.067884068 Cohort 2 
12 F 48 Non-Diabetic No 115.8060353 2.517522507 Cohort 1 
27 F 49 Non-Diabetic No 363.5195346 7.902598578 Cohort 1 
93 M 50 Non-Diabetic Yes 36.51424011 0.793787829 Cohort 4 
83 F 50 Non-Diabetic No 191.5011221 4.163067872 Cohort 1 
18 F 52 Non-Diabetic No 373.4086342 8.117579005 Cohort 1 
39 F 52 Non-Diabetic No 51.38008919 1.116958461 Cohort 1 
47 M 52 Type 2  Diabetic Yes 768.3027229 16.70223311 Cohort 2 
72 M 52 Non-Diabetic No 0.864973028 0.018803761 Cohort 1 
43 F 53 Non-Diabetic No 183.9980517 3.999957646 Cohort 1 
94 F 53 Non-Diabetic  No 202.6719279 4.405911476 Cohort 1 
154 F 53 non-Diabetic No 17.93962722 0.389991896 Cohort 1 
158 M 53 non-Diabetic No 196.9434107 4.281378494 Cohort 1 
73 M 54 Non-Diabetic No 142.5270775 3.098414728 Cohort 1 
168 M 54 Type 2 Diabetic  Yes 92.0612333 2.001331159 Cohort 2 
37 M 55 Type 2 Diabetic  Yes 86.11113817 1.871981265 Cohort 2 
111 F 55 Type 2 Diabetic  Yes 133.0713687 2.892855841 Cohort 2 
21 F 56 Non-Diabetic No 55.86321062 1.214417622 Cohort 1 
122 M 57 Type 2 Diabetic  Yes 138.2169058 3.004715344 Cohort 2 
31 M 58 Pre-Diabetic Yes 448.0842999 9.740963041 Cohort 4 
104 M 58 Type 2 Diabetic  Yes 4.436496225 0.09644557 Cohort 2 
164 F 58 Type 2 Diabetic Yes 35.04300608 0.76180448 Cohort 2 
5 F 59 Non-Diabetic No 31.11776644 0.676473183 Cohort 1 
34 M 59 Type 1 Diabetic No 50.06741188 1.088421997 Cohort 1 
61 F 61 Non-Diabetic No 868.1334798 18.87246695 Cohort 1 
121 F 61 Type 2 Diabetic Yes 74.97369122 1.629862853 Cohort 2 
173 F 61 non-Diabetic No 72.93751661 1.585598187 Cohort 1 
66 F 62 Non-Diabetic No 83.74502165 1.820543949 Cohort 1 
67 F 63 Non-Diabetic No 468.9488756 10.19454077 Cohort 1 
79 F 63 Non-Diabetic No 21.03565628 0.457296876 Cohort 1 
52 M 64 Type 2 Diabetic  No 82.44886038 1.79236653 Cohort 3 
55 F 64 Pre-Diabetic No 251.7377374 5.472559508 Cohort 1 
65 M 64 Type 2 Diabetic  Yes 256.449296 5.574984696 Cohort 2 
95 F 64 Non-Diabetic  No 57.26476292 1.244886151 Cohort 1 
152 F 64 Type 2 Diabetic Yes 74.84560351 1.627078337 Cohort 2 
51 F 65 Non-Diabetic No 108.7300275 2.363696249 Cohort 1 
117 M 65 Type 2 Diabetic  Yes 293.6872739 6.384505954 Cohort 2 
44 F 66 Type 2 Diabetic Yes 38.72528021 0.841853918 Cohort 2 
78 F 66 Type 2 Diabetic  Yes 140.423793 3.052691152 Cohort 2 
86 F 66 Non-Diabetic No 161.2458322 3.505344178 Cohort 1 
101 M 66 Type 2 Diabetic No 9.543999645 0.207478253 Cohort 3 
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106 F 66 Type 2 Diabetic  Yes 99.52963571 2.163687733 Cohort 2 
50 F 67 Type 2 Diabetic  Yes 517.951234 11.25980944 Cohort 2 
53 M 67 Non-Diabetic No 103.8222068 2.257004496 Cohort 1 
109 M 67 Type 2 Diabetic  Yes 201.7766782 4.386449527 Cohort 2 
110 M 67 Non-Diabetic  No 46.36347555 1.007901642 Cohort 1 
48 F 68 Non-Diabetic No 1077.345597 23.42055646 Cohort 1 
99 M 68 Type 2 Diabetic  No 14.80875453 0.321929446 Cohort 3 
153 M 68 Type 2 Diabetic  Yes 75.31167564 1.63721034 Cohort 2 
171 M 68 Type 2 Diabetic  Yes 82.37271764 1.790711253 Cohort 2 
29 F 69 Type 1 Diabetic No 185.001943 4.02178137 Cohort 1 
35 F 69 Type 2 Diabetic Yes 58.99903793 1.282587781 Cohort 2 
38 M 69 Type 2 Diabetic  Yes 104.7606194 2.277404769 Cohort 2 
54 M 69 Non-Diabetic No 150.4813062 3.271332744 Cohort 1 
25 F 70 Non-Diabetic No 294.6918761 6.406345132 Cohort 1 
33 F 70 Type 2 Diabetic  Yes 382.8984708 8.3238798 Cohort 2 
85 F 70 Non-Diabetic No 74.30824255 1.615396577 Cohort 1 
113 F 70 Type 2 Diabetic  No 67.98111663 1.477850362 Cohort 3 
6 F 71 Non-Diabetic No 3.30541E-09 7.18568E-11 Cohort 1 
36 M 71 Type 2 Diabetic  Yes 433.0382444 9.413874879 Cohort 2 
45 F 71 Type 2 Diabetic Yes 818.0051539 17.78272074 Cohort 2 
71 M 71 Type 2 Diabetic  Yes 114.5484176 2.490182991 Cohort 2 
81 F 71 Non-Diabetic No 47.08717353 1.023634207 Cohort 1 
102 M 71 Type 2 Diabetic  Yes 10.29310794 0.223763216 Cohort 2 
112 F 71 Type 2 Diabetic  No 37.79951042 0.821728487 Cohort 3 
16 F 72 Type 2 Diabetic  Yes 89.76080684 1.951321888 Cohort 2 
26 F 72 Type 2 Diabetic Yes 50.07815337 1.088655508 Cohort 2 
49 M 72 Type 2 Diabetic No 2987.608101 64.9480022 Cohort 3 
62 F 72 Non-Diabetic No 203.4573999 4.422986953 Cohort 1 
64 M 73 Non-Diabetic No 52.98366356 1.151818773 Cohort 1 
69 M 73 Type 2 Diabetic Yes 12.54978856 0.27282149 Cohort 3 
75 M 73 Type 1 Diabetic No 224.6667548 4.884059887 Cohort 1 
80 M 73 Type 2 Diabetic  Yes 69.47639843 1.510356488 Cohort 2 
163 F 73 Type 2 Diabetes Yes 375.9627401 8.173103045 Cohort 2 
24 M 74 Type 2 Diabetic Yes 161.120055 3.502609891 Cohort 2 
57 F 74 Type 2 Diabetic Yes 482.1800237 10.48217443 Cohort 2 
107 F 74 Type 2 Diabetic  No 118.1317075 2.568080598 Cohort 3 
116 M 74 Type 2 Diabetic  Yes 85.0948733 1.84988855 Cohort 2 
41 F 75 Non-Diabetic No 157.7306675 3.428927555 Cohort 1 
46 M 75 Non-Diabetic No 579.3427487 12.59440758 Cohort 1 
60 M 75 Non-Diabetic No 72.66859806 1.579752132 Cohort 1 
90 M 75 Non-Diabetic  No 294.1991839 6.395634433 Cohort 1 
119 M 75 Type 2 Diabetes  Yes 649.2852523 14.11489679 Cohort 2 
165 F 75 Type 2 Diabetic  Yes 154.0802046 3.349569665 Cohort 2 
32 M 76 Type 2 Diabetic  No 370.4981972 8.054308634 Cohort 3 
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59 F 77 Non-Diabetic No 475.7960225 10.34339179 Cohort 1 
70 M 77 Non-Diabetic No 144.178518 3.134315609 Cohort 1 
63 M 78 Non-Diabetic No 24.35716339 0.529503552 Cohort 1 
96 F 78 Type 2 Diabetic Yes 2.371553332 0.051555507 Cohort 2 
105 M 78 Type 2 Diabetic  Yes 211.2817328 4.593081149 Cohort 2 
114 M 79 Type 2 Diabetes No 56.49806174 1.228218733 Cohort 3 
118 M 79 Type 2 Diabetes Yes 74.36530997 1.616637173 Cohort 2 
97 M 80 Type 2 Diabetic No 25.12856177 0.546273082 Cohort 3 
98 M 80 Type 2 Diabetic  Yes 137.2505418 2.98370743 Cohort 2 
30 F 81 Type 2 Diabetic Yes 1121.045761 24.37056001 Cohort 2 
56 M 81 Non-Diabetic No 72.63126282 1.578940496 Cohort 1 
19 F 82 Non-Diabetic No 127.3287525 2.768016359 Cohort 1 
174 m 83 Type 2 Diabetic  Yes 266.584888 5.795323652 Cohort 2 
58 M 87 Type 2 Diabetic  Yes 177.4161674 3.856873204 Cohort 2 
108 M 88 Type 2 Diabetic  Yes 13.35216114 0.290264373 Cohort 2 
20 M 96 Non-Diabetic No 55.66117932 1.210025637 Cohort 1 




3.2 Comparison of age cohorts 
 
Comparison of the mean standard deviation, n-value, and coefficient of variation for the 
average absolute telomere length in each cohort over the various age ranges for participants over 
the age of 41 is presented to test our hypothesis. The distribution data necessary for statistical 
analysis (see Appendix 4) is included in the following three tables (Table 2, 3, and 4). These 
tables provide the mean standard deviation, n-value, and coefficient of variation for the average 
absolute telomere length values of Cohort 1 (Table 2), Cohort 2 (Table 3) and Cohort 3 (Table 4) 
across the ages of 41 to 100. Cohort 4 is not included as there were only two values, both falling 
within differing age ranges. 
The data pertaining to Cohort 1 across defined age ranges shows fluctuating values of 
mean average absolute telomere length per chromosome, starting with a relatively high value in 
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the age range of 41-50, decreasing across the 51-60 and 61-70 age range, increasing to its highest 
mean at the age range of 71-80, and then, finally decreasing in the final two age ranges (Table 2). 
The standard deviation is quite high for all age ranges, decreasing slightly during the 81-90 age 
range (Table 2). The coefficient of variation, which compares the standard deviation to the mean 
stays constant throughout the majority of the age ranges, only decreasing a great deal between 
the age range of 81-90 (Table 2). The number of individuals between 41 and 80 years of age are 
all high, ranging from 8 to 14 samples (Table 2). The number of individuals drop considerably 
after this, with only two data points between the 81-90 age range and a single data point between 
the 91-100 age range (Table 2). 
Table 2:  
 
Table 2: The sample distribution details for the average absolute telomere length per 
chromosome of the Cohort 1 samples over various age ranges. 
Age Range 
(Years) 41-50 51-60 61-70 71-80 81-90 91-100 
Mean 4.08120 2.8389505 3.2303020 4.4989484 2.1734784 1.2100256 
Standard 
Deviation 3.87520 2.4303078 2.6295446 3.9244354 0.8408036 N/A 
number 8 10 14 11 2 1 
Coefficient of 
Variation 0.949524 0.8560585 0.8140244 0.8723006 0.3868470 N/A 
 
 
The data pertaining to Cohort 2 across defined age ranges also shows to have fluctuating 
values of mean average absolute telomere length per chromosome, with the values beginning 
moderately, followed by them reaching their peak between the 71-80 age range and then 
decreasing down to moderate levels between the ages of 81 and 90 (Table 3). The mean value for 
the age range of 91-100 appears to be the highest, however, it is not a true mean value as it 
represents only one data point (Table 3). The standard deviation is high for most age ranges, with 
the first two age ranges having the lowest values (Table 3). The coefficient of variation displayed 
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a similar trend, with the first two age ranges having the lowest values. n values were low in the 
41-50, 81-90, and 91-100 age ranges, moderate in the 51-60 age range, and high in the 61-70 and 
71-80 age ranges (Table 3). 
 
Table 3: The sample distribution details for the average absolute telomere length per 
chromosome of the Cohort 2 samples over various age ranges. 
Age Range (Years) 41-50 51-60 61-70 71-80 81-90 91-100 
Mean 3.02956 2.1065376 3.3698779 4.2260403 3.3141537 4.5631466 
Standard Deviation 1.36002 0.9082142 3.0595772 4.0979523 2.7923696 N/A 
number 2 5 16 16 3 1 
Coefficient of Variation 0.44892 0.4311407 0.9079193 0.9696908 0.8425588 N/A 
 
The statistical data for Cohort 3 represents the data of two age ranges: 61-70 and 71-80 
(Table 4). The mean, standard deviation and number of individuals are both higher in the 71-80 
age range than the 61-70 age range (Table 4). However the Coefficient of Variation for both age 
groups is fairly similar (Table 4). 
 
Table 4: The sample distribution details for the average absolute telomere length per 
chromosome of the Cohort 3 samples over various age ranges. 
Age Range (Years) 61-70 71-80 
Mean 0.7739247 2.643721907 
Standard Deviation 0.883851 3.122609933 
number 3 5 
Coefficient of Variation 1.1420373 1.181141604 
 
3.3 Comparison of telomere lengths between cohorts 
 
The difference in mean average absolute telomere length for each of the four cohorts 
between the ages of 41 and 100 were compared (Figure 6). The error bars visually display the 
standard deviation of each sample set (Figure 6). The ‘A’ and ‘B’ values denote p-values 
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obtained from a t-test (Appendix D). Cohort 4, and anything belonging to the age range of 91-
100 do not have error bars because they are single data points (Figure 6). They were included for 
the sake of completeness, but do not indicate any trends due to the number of individuals. The 
Cohort 1 mean is noticeably higher than that of Cohort 2 for the first two age ranges (both have 
B p-values). In the age ranges of 61-70 and 71-80, the means are nearly identical, and both have 
p-values classified as ‘A’. In the age range of 81-90, the mean value of Cohort 2 is noticeably 
greater than that of Cohort 1. Through the age ranges of 61-70 and 71-80, Cohort 3 has a much 
smaller mean value than both Cohorts 1 and 2. 
 
 
Figure 6: The mean average absolute telomere length per chromosome of Cohort 1, Cohort 2, 




The legend at the right describes which cohort group corresponds to which bar (Figure 6). T-tests 
were completed to determine the differences between the mean average absolute telomere length 
of the Cohort 1and Cohort 2 samples. The ‘A’ indicates a p-value between 0.4 and 0.5 and a ‘B’ 
indicates a p-value between 0.2 and 0.3 (Figure 6). Error bars indicating standard deviation were 
included for the Cohort 1 and Cohort 2 samples (Figure 6). Error bars were not generated for 
Cohort 1 and Cohort 2 samples which fell into the age range of 91-100, as there was only one 
data point for each (Figure 6). Similarly, error bars were not included for the Cohort 4 samples as 
there was only a single data point in two separate age ranges (Figure 6). 
 
3.4 Statistical Analysis 
 
 Statistical analyses were completed to test for statistically significant differences in the 
sets of average absolute telomere length data between cohort groups.  
Linear regression analysis was completed using IBM SPSS Statistics Data Editor for 
Cohort 1 (Table 5), Cohort 2 (Table 6), and Cohort 3 (Table 7) to determine if age impacted the 
average absolute telomere length for these cohort groups. It was found that, through the analysis 
of all three linear regression models, age does not have a statistically significant impact (a p-
value greater than 0.05) on the average absolute telomere length. Because of this, age was not 






Table 5: The model summary for the regression model analysis showing the impact age has on 













Change df1 df2 
Sig. F 
Change 
1 .006a .000 -.023 3.128669 .000 .002 1 44 .967 
a. Predictors: (Constant), Age 
b. Dependent Variable: Average Absolute Telomere Length per Chromosome 
 
The regression analysis between age and average absolute telomere length for Cohort 1 (Table 5) 
shows that age does not have a significant impact on that average absolute telomere length, 
giving a p-value of 0.967 (a value higher than 0.05). Both the R Square value and the adjusted R 
Square value show that 0% of the variance in the average absolute telomere length is determined 
by the age.  
 
 
Table 6: The model summary for the regression model analysis showing the impact age has on 













Change df1 df2 
Sig. F 
Change 
1 .139a .019 -.005 3.2184465 .019 .806 1 41 .375 
a. Predictors: (Constant), Age (years) 
b. Dependent Variable: Average Absolute Telomere Length per Chromosome 
 
The regression analysis between age and average absolute telomere length for Cohort 2 (Table 6) 
shows that age does not have a significant impact on that average absolute telomere length, 
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giving a p-value of 0.375 (a value higher than 0.05). The R Square value indicates that 1.9% of 
the variance in the average absolute telomere length is determined by the age. The adjusted R 
Square value indicates that 0% of the variance in the average absolute telomere length is 
determined by the age. 
 
 
Table 7: The model summary for the regression model analysis showing the impact age has on 













Change df1 df2 
Sig. F 
Change 
1 .265a .070 -.085 2.702135336001004 .070 .453 1 6 .526 
a. Predictors: (Constant), Age (Years) 
b. Dependent Variable: Average Absolute Telomere Length per Chromosome 
 
The regression analysis between age and average absolute telomere length for Cohort 3 (Table 7) 
shows that age does not have a significant impact on that average absolute telomere length, 
giving a p-value of 0.526 (a value higher than 0.05). The R Square value indicates that 7% of the 
variance in the average absolute telomere length is determined by the age. The adjusted R Square 
value indicates that 0% of the variance in the average absolute telomere length is determined by 
the age 
 
Two-tailed t-tests were completed using Microsoft Excel 2016 to test for a statistically 




Table 8: T-Test analysis comparing the statistical difference of the average absolute telomere 
length between Cohort 1 and Cohort 2. 









The t-test analysis comparing Cohort 1 and Cohort 2 values (Table 8) did not generate any p-
values below 0.05, indicating no statistically significant difference between these sets of data. 
 
 
Table 9: T-Test analysis comparing the statistical difference of the average absolute telomere 
length between Cohort 1 and Cohort 3. 




The t-test analysis comparing Cohort 1 and Cohort 3 values between the age ranges of 61-70 and 
71-80 (Table 9) showed a p-value less than 0.05 for the age range of 61-70. This potentially 
indicates a statistically significant difference between these two cohorts for that age range. The 
p-value for these two cohorts between the age range of 71-80 was greater than 0.05, indicating 
no statistically significant difference between the data sets for this age range. 
 
Table 10: T-Test analysis comparing the statistical difference of the average absolute telomere 
length between Cohort 2 and Cohort 3. 






The t-test analysis comparing Cohort 2 and Cohort 3 between the ages of 61-70 and 71-80 (Table 
9) displays a p-value less than 0.05 for the age range of 61-70. This could indicate a statistically 
significant difference between these two cohorts for that age range. Conversely, the p-value for 
these two cohorts between the ages of 71-80 was greater than 0.05, indicating no statistically 
significant difference between the cohort groups for this age range. 
 
Table 11: A one-way ANOVA test comparing the statistical difference of the average absolute 
telomere length between Cohort 1, Cohort 2 and Cohort 3. 
ANOVA summary   
F 0.008366 
P value 0.9917 
P value summary ns 
Significant diff. among means (P < 
0.05)? No 
R square 0.0005574 
 
The ANOVA test summarized in Table 11 was created using GraphPad Prism 7.05. The p-value 
obtained was 0.9917 (larger than 0.05), indicating the absence of a statistical difference for the 
average absolute telomere lengths between Cohort 1, Cohort 2 and Cohort 3.  
 
3.5 Method Verification 
 
The methods were evaluated using controls, standards and quantification. All controls and 
standards were run with every qPCR. If any of the extraction negative and qPCR negative 
controls were deemed compromised the analysis was repeated. The standards used for 
calculation purposes were amplified on the same plate at the test samples so that a standard curve 
could be determined for every run since there is the possibility for inter-run variability. All 
extractions were quantified to ensure the appropriate amount of DNA was added to each reaction 
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as optimized. Some of the samples were randomly checked for inter-run variability by replication 
(Table 5). For example the average absolute telomere length for the same sample across two 




Table 12: A comparison of qPCR results for the same unknown sample extracted and purified 
separately and analyzed through separate qPCR amplifications. 
Sample 
Absolute telomere 
length per  genome 
(kb/genome) 
Average absolute telomere 
length per chromosome 
(kb/chromosome) Date Run 
58 177.4161674 3.856873204 
August 5, 
2018 






The average absolute telomere lengths for both analyses of sample 58 (on August 5th, 2018 and 










4.1 Precision and accuracy of results 
 
There were relatively high standard deviations in this data when comparing the 
coefficient of variation to their means (Table 2-4 and Figure 6). This indicates a large spread of 
data points and low precision for most of the age ranges of the data. This result is likely due to 
the complexity and number of factors that affect the rate of telomere shortening. Due to the 
limited sample size, the results were organized by age ranges of ten years and were not further 
subdivided by sex, ethnic origin, health, caloric intake, lifestyle, duration of treatment, or 
treatment dose even though there is evidence that all these factors affect telomere shortening (77, 
85, 84, 11, 9). The varying combinations of these factors in the tested individuals is what could 
have led to this large standard deviation. This, along with some slight variability of the qPCR 
method could have been the reason for the diverse range in data. 
Although the methodology is consistent with other studies, it would have contributed to 
some degree of imprecision, as telomere analysis via qPCR has a variability between 5-10% 
(50). This effect, however, seems to be minimal as repeated analysis of the same unknown 
sample led to very highly similar results (Table 5). 
 Comparing the data generated in this study to literature values can assist in determining 
accuracy of the data itself. The mean average absolute telomere length for Cohort 1 and 2 range 
from below 5 kb/chromosome to above 2 kb/chromosome (Figure 6). This is similar, albeit 
slightly lower, than the values obtained from other studies (77, 78). Frenck et al. (78) found that, 
between an individual’s early 40s and late 70s, telomere length decreased from around 10.5 to 8 
kb/chromosome. Findings from Bischoff et al. (77), combined with data from Benetos et al. (41) 
indicate telomere length from whole blood decreases from 8.5 to 7.5 kb/chromosome between an 
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individual’s early 40s and late 70s. Although some samples were obtained from healthy 
individuals who were simply interested in participating in the study, many of the participants 
were recruited from Curans Heart Centre, a clinic for individuals with cardiac health concerns. 
Research has shown that cardiovascular diseases can result in increased telomere attrition (79). 
Particularly, heart conditions such as artery stiffness, the advanced stages of atherosclerosis, and 
coronary heart disease have all been found to cause an increased rate of telomere shortening (80, 
81, 82). Perhaps this could explain why the average absolute telomere length was slightly lower 
than expected. This could also be a possible explanation for the high variation of data. The 
results of this study show a slight decrease in Cohort 1’s average absolute telomere length over 
time from the age of 41 to 100 (Table 2 and Figure 6). This does follow the expected trend of a 
gradual decrease in telomere length from young adulthood to old age (78). The control group 
displaying the expected gradual attrition in telomere length does lend further support to the 
accuracy of the results.  
 
4.2 The effects of metformin use on average absolute telomere length 
 
In the earlier age ranges (41-50, and 51-60), the mean average absolute telomere length 
for Cohort 2 begins by being noticeably lower than the mean average absolute telomere length of 
Cohort 1 (Table 2, 3 and Figure 6). However, in the age ranges of 61-70 and 71-80, the mean 
average absolute telomere length for both Cohort 1 and 2 are nearly the same, indicating a 
relatively slower decrease in telomere length for Cohort 2 with advanced age when compared to 
the negative control (Table 2, 3 and Figure 6). This can be seen further in the 81-90 and 91-100 
age ranges in which the mean average absolute telomere length of Cohort 2 is noticeably higher 
than that of Cohort 1 (Table 2, 3 and Figure 6). It should be noted that these last two age ranges 
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have few data points (2 for Cohort 1 and 3 for Cohort 3 in the 81-90 age range, and 1 each for 
the 91-100 age range), so any conclusions relating to individuals over the age of 80 is more 
suspect than that of the younger age ranges. 
This relative slowing of telomere attrition in Cohort 2 could be due, in part, to the 
duration of metformin treatment. It has been shown in previous research that metformin is most 
effective at improving longevity with extended treatments (11). This could explain why telomere 
attrition in Cohort 2 slowed with age relative to the negative control. After the age of 45-50, the 
risk for developing type 2 diabetes increases (45). It could be inferred that most patients were 
likely diagnosed with type 2 diabetes during middle age and would have started the first-line 
metformin treatment around this age, resulting in Cohort 2 having relatively longer mean average 
absolute telomere lengths as time progressed and more years were spent taking the drug. 
Although these trends appear to be present through visual interpretation of Figure 6, the 
statistical t-tests did not show any statistical difference between the data from Cohort 1 and 2 
(Table 8). This was likely due to the relatively large spread in data points and subsequent large 
standard deviations (Table 2, Table 3). However, Cohort 3 has a considerably lower mean 
average absolute telomere length than both Cohort 1 and 2 (Table 2-4). For the age range of 61-
70, the t-test values seem to indicate that there is a significant difference between both Cohorts 1 
and 3, and Cohorts 2 and 3, with p-values of 0.0083 and 0.0074 respectively (Table 9, Table 10). 
The differences in mean average absolute telomere length for the age range of 71-80 did not 
show statistically significant values, giving p-values of 0.167591633 and 0.192657552 for 
Cohort 1 and Cohort 3 respectively (Table 9, Table 10).  
The one-way ANOVA test (Table 11), which compared all three cohort groups along the 
age range of 61-70, provided results which conflicted with the t-tests in Table 9 and Table 10. 
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This ANOVA test did not find a statistically significant difference between the three cohorts for 
the age range of 61-70 (Table 11). This discrepancy could be present because the one-way 
ANOVA test compares all three means against each other simultaneously, whereas both t-tests 
specifically compared Cohort 3 with Cohorts 1 and 2 separately. Perhaps the one-way ANOVA 
test was not able to register a statistically significant difference due to the variance of all three 
datasets, yet differences between the two cohorts exist. It is also possible the statistically 
significant p-values obtained from the t-tests were false positives (type I error). 
Overall, it appears that there might be some evidence to support the notion that the mean 
average absolute telomere length for diabetics not taking metformin is lower than the mean 
average absolute telomere length for type 2 diabetics taking metformin as well as healthy control 
samples. However, due to conflicting statistical analyses and the fact that this trend is only 
observed within a ten year age range, no definitive conclusions can be made at this time.  
 
4.3 Study limitations and future directions 
 
A limitation with this study is the relatively low sample size, specifically for Cohorts 3 
and 4. With greater numbers of samples from these two cohort groups, a more balanced study 
could be undertaken, proving more definitive conclusions about metformin’s effect on telomere 
length. It is likely that our relatively small numbers of individuals in each age group were not 
large enough to resolve the differences in telomere length seen in the previous studies with their 
hundreds of subjects. In future studies it might be pertinent to selectively recruit participants of 
similar sex, ethnic origin, health status, length of treatment, and dosage. Improved control of 
these external variables could result in more precise findings. 
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It may also prove useful, in future studies, to explore alternative analytical techniques for 
analyzing telomeres. The qPCR method is known to have a high degree of variability within its 
final results, lending to a higher variance of the data. Perhaps a method such as the Southern Blot 
technique, which is highly reproducible and considered to be quite precise, would be a more 




 Although this preliminary study was able to identify several trends in how metformin and 
type 2 diabetes can affect telomere length, a conclusive link between metformin use and 
telomere length is still yet to be firmly established. All calculated telomere lengths were 
reasonable when compared to other published works, however, due to high standard deviations, 
statistical significance was not established between type 2 diabetics taking metformin (Cohort 2) 
and negative control samples (Cohort 1). Despite this, the mean average absolute telomere length 
did appear to have a decrease in its attrition rate when compared to the negative control values. 
This led to the mean average absolute telomere length of Cohort 2 matching and later surpassing 
the Cohort 1 levels with age.  
There did, however, appear to be a difference in average absolute telomere length 
between type 2 diabetics not taking metformin (Cohort 3) and Cohorts 1 and 2. Cohort 3 
appeared to have a reduced mean average absolute telomere length when compared to both 
Cohort 1 and Cohort 2. This lower telomere length in Cohort 3 when compared to Cohort 2 
indicates that metformin use may slow the process of telomere shortening in older adults. 
However, although t-testing indicates that this was statistically significant between the age of 71-
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80, one-way ANOVA testing showed no statistical difference between all three cohorts. Because 
of this, no definitive links between metformin and telomere length can be stated. 
 To determine more definitive results, a greater amount of data would likely need to be 
collected and balanced more evenly across the four cohort groups. To improve specificity, it may 
be prudent for future studies in this area to factor in variables such as sex, ethnic origin, exercise, 
caloric intake, lifestyle, health, metformin treatment length, and metformin dosage. It may also 
be useful to measure telomere length through alternative analytical techniques such as the 
Southern blot technique to compare and validate the measurement methods employed. Overall, 
this evidence from this study does hint at possible geroprotective effects for metformin, and 
would warrant further in-depth studies in the future. 
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Appendix A: Sample Calculations 
 
Determining how much double distilled H2O is required to dilute the purified DNA sample to 5 
ng/μL 
 Final volume for the qPCR - ready purified DNA solution = (20 μL (arbitrary starting 
volume) x the concentration determined from the Quantus fluorometer)/(5 ng/µL (known 
concentration needed for the qPCR)) 
 
Amount of double distilled water to add to purified DNA solution (to achieve a concentration of 
5 ng/μL) = the final volume for the qPCR - ready purified DNA solution (calculated above) -20 
μL (the arbitrary starting volume) 
 
 
Calculations for the Starting Quantity (length) of the Telomere (Telo) standards for the lowest 
dilution in the dilution series (1/10,000) 
 The oligomer standard is 84 bp in length (TTAGGG multiplied by 14), also having a 
molecular weight of 26667.2 g/mol (1).  The weight of one molecule is determined by dividing 
the molecular weight (2.6667E+04 g/mol) by Avogadro’s Number (6.02E+23 mol) = 0.44 × 10-
19 g. 
A 1/10 dilution of the telo standard has a mass of 349.33 ng/μL. Multiply this value by 4 
μL (the amount of sample used in each PCR reaction) to get 1397.32 g per reaction. Divide this 
number by 1000 to get the mass per reaction for a 1/10,000 dilution (the highest concentration in 
dilution series). This equates to 1.39732 g per reaction. To put the units into picograms per 
reaction, this value is multiplied by 1000, giving 1,397,32 pg per reaction.  
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Therefore, there are 1,397,32 pg/0.44E-19 = 3.15436E10 molecules of oligomer in the 
telo standard. 
The amount of telomere sequence in the telo standard is calculated: 3.15436E10 × 84 
/(oligomer length) = 2.6497E06. This is then divided by 1000 to give the value in kb in the 
1/10,000 serial dilution: 2.6497E09 kb 
 
Calculations for the Starting Quantity (length) of the 36B4 standards for the lowest dilution in 
the dilution series (1/10) 
 
The synthesised 36B4 oligomer standard is 75 bp in length with a MW of 23268.1 g/mol. 
The weight of one molecule is the molecular weight divided by Avogadro’s number. The mass of 
the of the 36B4 oligomer standard is: (2.32681E+04 g/mol)/(6.02E+23 mol) = 
0.38 × 10-19 g. 
 
The highest concentration standard (SCG STD A) had (360.00ng/μL *4 μL = 1440 ng) 
of the 36B4 oligomer standard for a 1/10 dilution. This is equivalent to 1440 pg per reaction for 
a 1/10,000 dilution. 
 
Therefore, there are (1440E-12 g)/ (0.38E-19) = 3.7256E10 copies of the 36B4 amplicon in the 
36B4 standard. Divide this value by 2 to get 1.86282E10 diploid genome copies for the 1/10,000 
dilution 
 




This value is then multiplied by 75 base pairs to give: 1.4367E+14 kb. 
 





















Appendix C: Analyzing qPCR Amplification Curves and Determining 
Average Absolute Telomere Length 
 
 Eighteen qPCR amplifications were required to obtain all the data for this study. 
Including all eighteen amplification curves, standard curve calculations, standard curves, and 
final calculations would be quite cumbersome and rather inefficient, a sample of only one qPCR 
amplification is included here for reference. All eighteen amplifications were processed 
identically to the one shown here, and the resultant data from all amplifications can be found in 
Table 1. 
Below is the amplification curve (Figure 8). The CFX manager software was used to 
analyze the qPCR data and it measure the amount of amplification cycles which crossed a 
predetermined threshold level of reflective fluorescent units (RFUs). This generates a value 
known as Cq, which is analogous to the cycle threshold (Ct).  
 
 
Figure 7: A sample of amplification curves from the qPCR amplification reaction run with a 
Biorad Real Time System C1000 Thermocycler, detected with a CFX96 Optics Module, and 





The known concentrations of the telomere standards are plotted alongside the resultant 
Cq values obtained from the CFX Manager Software to create a telomere length standard curve 
with a known slope (Table 8, Figure 9).  
 
Table 15: Resultant qPCR data and nucleic acid quantification data needed to construct a 








length (kb) Cq Average 
100K 0.001217 9293454.5 6.968177179 22.94 
1M 0.0001217 929345.45 5.968177179 26.04 




Figure 8: The resultant standard curve obtained from the LOG quantity of telomeres and the Cq 
values (Table 15). The equation of the line is y = -3.337x + 46.11 and the r2 value is 0.998. 
 
 
Similarly, the known concentrations of the 36B4 standards are plotted alongside the 
resultant Cq values obtained from the CFX Manager Software to create a (single genome copy 
standard curve with a known slope (Table 9, Figure 10).  
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Table 16: Resultant qPCR data and nucleic acid quantification data needed to construct a single 











100K 0.00066 34736842 7.540790335 11.267 
1M 0.000066 3473684.2 6.540790335 17.507 




Figure 9: The resultant standard curve obtained from the LOG quantity of telomeres and the Cq 




Lastly, the unknown samples that were amplified are tested. The sample have their Cq 
values compared to each standard curve, with the samples amplified using telomere primers 
compared to the telomere standard curve and the samples amplified using 36B4 primers 
compared to the single genome copy standard curve. For this, the log (telomere length (kb)) and 
log (single genome copies) can be calculated. The antilog function can be used convert to units 
of telomere length (kb) and single genome copies. The absolute telomere length per genome can 
be determined by dividing the calculated telomere length (kb) by the number of single genome 
copies. This number can be divided by 46 to obtain the average absolute telomere length per 
chromosome (See Table below for how this can be completed) 
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Table 17: Data required for the calculation of the absolute telomere length genome (kb/genome) 




































36 20.33 23.1 7.72550195 5.088975694 53149838.3 122737.0539 433.0382444 9.413874879 
67 17.727 19.665 8.5055439 5.834418403 320290385 682996.3815 468.9488756 10.19454077 
40 19.257 21.665 8.04704825 5.400390625 111441833 251414.6757 443.2590608 9.636066539 
49 16.155 21.2 8.97662571 5.501302083 947601439 317177.2894 2987.608101 64.9480022 
46 19.247 22.187 8.05004495 5.287109375 112213459 193690.9704 579.3427487 12.59440758 
10 18.63 22.15 8.23494156 5.295138889 171767725 197305.3625 870.5679517 18.92539025 
7 23.047 25.387 6.91129757 4.592664931 8152627 39143.97547 208.2728414 4.527670466 
28 21.49 20.133 7.37788433 5.732855903 23871753.8 540574.9325 44.1599349 0.959998585 
72 28.667 22.173 5.22715013 5.290147569 168713.616 195050.7252 0.864973028 0.018803761 
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